首页> 外国专利> 1-(OMEGA-CARBOXYALKYL)-3-3 OR 4-(1-PHENYLALKOXY OR 1-PHENOXYALKYL)BENZOYLINDOLE DERIVATIVES HAVING STEROID 5ALPHA-REDUCTASE INHIBITORY ACTIVITY AND MEDICAMENTS

1-(OMEGA-CARBOXYALKYL)-3-3 OR 4-(1-PHENYLALKOXY OR 1-PHENOXYALKYL)BENZOYLINDOLE DERIVATIVES HAVING STEROID 5ALPHA-REDUCTASE INHIBITORY ACTIVITY AND MEDICAMENTS

机译:具有甾类5α-还原酶抑制活性和药物的1-(ω-羧基烷基)-3- [3或4-(1-苯基烷基或1-苯氧基)苯甲酰基]吲哚衍生物

摘要

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein X is O, NH, N(C1-C4 alkyl), C1-C4 alkylene, C2-C4 alkenylene or C2-C4 alkynylene, said alkylene, alkenylene and alkynylene groups being optionally substituted by C1-C4 alkyl or aryl; Y is C1-C6 alkylene optionally substituted by C1-C6 alkyl; R is H, OH, halo, C1-C4 alkyl or C1-C4 alkoxy; R1, R2, R3 and R4 are each independently selected from H, C1-C4 alkyl, C1-C4 alkoxy, OH, halo and CF3; one of R6, R7 and R8 is C1-C15 alkyl or a group of the formula -Z(C1-C15 alkyl), -Z(aryl) or -Z(C3-C7 cycloalkyl), said alkyl group being optionally interrupted by O, S(O)q, NH or N(C1-C6 alkyl), and said alkyl group and the alkyl group of said -Z(C1-C15 alkyl) group being optionally substituted by C1-C10 alkoxy, aryl, C3-C7 cycloalkyl or a group of the formula -Z(aryl), and the remainder of R6, R7 and R8 and R5 and R9 are each independently selected from H, C1-C4 alkyl, C1-C4 alkoxy, halo and halo(C1-C4 alkyl); R10 is COOH, COOR11 or CONR12R13; R11 is a biolabile ester-forming group; R12 and R13 are each independently selected from H and C1-C4 alkyl; Z is O, S(O)q, NH or N(C1-C6 alkyl); q is 0, 1 or 2; and ''aryl'' used in the definitions of X, R6, R7 and R8, means phenyl optionally substituted by C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, OH, halo, CF3, halo(C1-C6 alkyl), nitro, amino, C2-C6 alkanamido, C2-C6 alkanoyl or phenyl: together with pharmaceutical compositions containing, processes for the preparation of and uses of, such compounds.
机译:本发明提供式(I)的化合物及其药学上可接受的盐,其中X为O,NH,N(C 1 -C 4烷基),C 1 -C 4亚烷基,C 2 -C 4亚烯基或C 2 -C 4亚炔基,所述亚烷基,亚烯基亚炔基任选被C 1 -C 4烷基或芳基取代; Y为任选被C 1 -C 6烷基取代的C 1 -C 6亚烷基; R为H,OH,卤素,C1-C4烷基或C1-C4烷氧基; R 1,R 2,R 3和R 4各自独立地选自H,C 1 -C 4烷基,C 1 -C 4烷氧基,OH,卤素和CF 3; R 6,R 7和R 8中的一个为C 1 -C 15烷基或式-Z(C 1 -C 15烷基),-Z(芳基)或-Z(C 3 -C 7环烷基)的基团。所述烷基任选被O,S(O)q,NH或N(C 1 -C 6烷基)间断,并且所述烷基和所述-Z(C 1 -C 15烷基)的烷基任选被C 1取代-C 10烷氧基,芳基,C 3 -C 7环烷基或式-Z(芳基)的基团,以及R 6,R 7和R 8以及R 5和R 9的其余部分各自独立地选自H,C 1 -C 4烷基,C 1 -C 4烷氧基,卤素和卤素(C 1 -C 4烷基); R 10为COOH,COOR 11或CONR 12 R 13; R 11为生物不稳定的酯形成基团。 R 12和R 13各自独立地选自H和C1-C4烷基; Z是O,S(O)q,NH或N(C1-C6烷基); q是0、1或2; X,R 6,R 7和R 8的定义中所用的“芳基”和“芳基”是指任选地被C 1 -C 6烷基,C 1 -C 6烷氧基,C 2 -C 6烯基,OH,卤代,CF 3,卤代(C 1 -C 6烷基),硝基,氨基,C 2 -C 6烷酰胺基,C 2 -C 6烷酰基或苯基:以及包含此类化合物的药物组合物,其制备方法和用途。

著录项

  • 公开/公告号NZ243687A

    专利类型

  • 公开/公告日1994-12-22

    原文格式PDF

  • 申请/专利权人 PFIZER INC;

    申请/专利号NZ19920243687

  • 申请日1992-07-23

  • 分类号C07D209/12;C07D209/42;A61K31/40;

  • 国家 NZ

  • 入库时间 2022-08-22 04:18:38

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号